Drug intelligence / Profile preview

levodopa + standard care

Development stage
Unknown
Lead developer
Roche
Modality
Small Molecules
Administration
Oral, Inhalation, Enteral
01

Overview

Levodopa + standard care refers to the use of levodopa, a dopamine precursor, in combination with the usual non-experimental therapies for Parkinson's disease (PD). Levodopa is converted to dopamine in the brain and is considered the most effective pharmacologic treatment for alleviating motor symptoms such as bradykinesia and rigidity in PD. Standard care typically includes supportive measures like physical therapy, occupational therapy, speech therapy, and may include other medications as clinically indicated. Levodopa is often administered with a peripheral decarboxylase inhibitor (such as carbidopa) to increase its bioavailability in the brain and reduce side effects. The mechanism of action involves replenishing depleted dopamine levels in the striatum by providing a substrate that crosses the blood-brain barrier and is then converted into active dopamine[6][8][10]. This combination remains first-line therapy for symptomatic management of Parkinson's disease.

02

Targets

DRD (Dopamine receptors)AR (Adrenergic receptors)SLC7A5 (Large neutral amino acid transporter small subunit 1)DDC (Aromatic L-amino acid decarboxylase)COMT (Catechol-O-methyltransferase)

Beyond the preview

Go deeper on levodopa + standard care.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on levodopa + standard care.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call